Fresenius Kabi has acquired Akorn, a U.S.-based manufacturer and marketer of prescription and over-the-counter pharmaceutical products, for approximately $4.3 billion. The deal is expected to close by early 2018. The agreement and transaction have been approved by the boards of both companies and will be recommended by Akorn’s board to its shareholders. “Joining our two companies and product portfolios will strengthen and diversify both businesses,” said John Ducker, president and chief execu...